
We are delighted to introduce Rhett Guo, the 2026 recipient of the British Association of Lung Research and Breathing Matters (BALR–BM) Summer Studentship, a programme we proudly support to nurture the next generation of respiratory researchers working in interstitial lung disease (ILD) and lung infections.
Rhett is a BSc Applied Medical Sciences student at University College London with a strong interest in respiratory medicine, epithelial biology, and the mechanisms underlying lung fibrosis. Through this studentship, he hopes to further develop his research skills and gain a deeper understanding of how translational respiratory research can contribute to future therapeutic research in respiratory disease.
His project, “Defining the role of mTOR signalling in the emergence and persistence of damage-associated transitional progenitors (DATPs) during alveolar epithelial differentiation and fibrosis”, examines the involvement of mTOR signalling in the appearance and persistence of DATPs in models of alveolar epithelial differentiation and fibrotic injury. Using human alveolar organoid models, the project aims to better understand how altered epithelial cell states may contribute to impaired lung repair in interstitial lung disease.
This studentship reflects our ongoing commitment to investing in early-career researchers whose work has the potential to improve outcomes for people living with ILD and lung infections.
We look forward to following Rhett’s progress over the summer and sharing updates on his findings later in the year.
Recent Articles
- First new IPF licenced medicine in a decade
- Understanding the biology of PPFE
- Meet this year’s BALR-BM summer student
- How common is muscle loss in lung fibrosis?
- July 2026 Newsletter
- Could a vaccine treat IPF?
- Thanking Edmonton WMC Club for charity of the year support
- Our new merchandise store is LIVE🌍
- Craft stall bulletin, June 2026
- Thank you, Cunningtons LLP, for 2025-26 support
- Life after tuberculosis
- March 2026 Newsletter
- Living with Bronchiectasis Community Days 2026
- Brinsupri™: First medicine licensed for bronchiectasis in the UK
- PET scans offer hope for SSc-ILD patients



